13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01111656March 200715/3/2010Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bSWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study)Relapsing-remitting Multiple SclerosisDrug: Interferon beta-1b group;Drug: Interferon beta-1b/Atorvastatin groupUniversity Hospital Inselspital, BerneViollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, SwitzerlandCompleted18 Years67 YearsBoth28Phase 2Switzerland
2NCT00818103January 200631/12/2008Characteristic Study on Chinese Patients With Multiple SclerosisCharacteristic Study on Chinese Patients With Multiple SclerosisMultiple SclerosisDrug: atorvastatin;Drug: ß-interferon;Drug: EPOSun Yat-sen UniversityThird Affiliated Hospital, Sun Yat-Sen UniversityRecruitingN/A65 YearsBoth600N/AChina
3EUCTR2005-001009-25-IT16/07/200515/03/2006Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNAEfficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA Multiple sclerosis treatment
MedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: TORVAST*10CPR 10MG
INN or Proposed INN: Atorvastatin
Trade Name: TORVAST*10CPR 10MG
INN or Proposed INN: Atorvastatin
DR DIMENSIONE RICERCANULLNot RecruitingFemale: yes
Male: yes
Italy
4NCT00094172May 200514/10/2004Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple SclerosisA Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)Multiple SclerosisDrug: Atorvastatin;Drug: PlaceboNational Institute of Allergy and Infectious Diseases (NIAID)Immune Tolerance Network (ITN)Completed18 Years55 YearsAll82Phase 2United States;Canada
5NCT00942591May 200517/7/2009Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1bEfficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.Multiple SclerosisDrug: Interferon beta 1b;Drug: AtorvastatinUniversity Hospital Inselspital, BerneCRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 BaselCompleted18 Years55 YearsBoth77Phase 2Switzerland
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00137176October 200426/8/2005EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple SclerosisEARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple SclerosisMultiple SclerosisDrug: RebifUniversity of North Carolina, Chapel HillNULLCompleted18 Years60 YearsBoth30N/AUnited States
7NCT00103974July 200417/2/2005Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple SclerosisA Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple SclerosisMultiple SclerosisBiological: BHT-3009-01Bayhill TherapeuticsNULLCompleted18 Years65 YearsBoth30Phase 1United States;Canada
8NCT00616187October 20035/2/2008Atorvastatin in Relapsing-Remitting Multiple SclerosisOral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: interferon beta treatment to add-on atorvastatin treatment;Drug: untreated to atorvastatin treatmentCharite University, Berlin, GermanyGerman Research Foundation;German Federal Ministry of Education and Research;PfizerCompleted18 Years55 YearsAll41Phase 2NULL